ArticleAmerican journal of translational research2025
Alternating intravesical instillation of Bacillus Calmette-Guérin and
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the role of alternating intravesical instillation of Bacillus Calmette-Guérin (BCG) and
methodsWe retrospectively reviewed the clinical data from 115 HR-NMIBC cases who underwent transurethral resection of bladder tumors (TURBT) at Gongli Hospital of Shanghai Pudong New Area between March 2021 and January 2023. Patients were grouped based on postoperative management: a control group (n=51) treated with standard gemcitabine instillations and an intervention group (n=64) given alternating BCG and PA instillations. This study assessed 1- and 2-year recurrence, recurrence-free survival, safety (gastrointestinal reactions, fever, bladder irritation symptoms, and hematuria), serum tumor markers, and life quality. Univariate and multivariate Cox proportional hazards analyses were applied to identify the recurrence predictors. A nomogram predictive model was further developed for postoperative recurrence risk estimation, and its performance was later validated.
resultsDespite an equivalent 1-year recurrence rate, the intervention group showed a lower 2-year recurrence rate, prolonged recurrence-free survival, and superior safety (fewer adverse events) than controls. The intervention group also showed decreased post-treatment serum tumor marker concentrations and greater life quality enhancement relative to the control cohort. Univariate and multivariate analyses identified tumor number ≥3 (P=0.036), high-grade tumors (P=0.040), and gemcitabine monotherapy (P=0.035) as independent predictors for 2-year recurrence. The nomogram's scoring system reliably associated elevated risk points with heightened recurrence risk, demonstrating strong discrimination and reliable calibration in medium-to-high-risk ranges.
conclusionsAlternating intravesical BCG and PA instillations markedly decreases 2-year postoperative recurrence on the premise of favorable safety in HR-NMIBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.